コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 diated activation with isoproterenol, a beta-adrenergic receptor agonist.
2 trains with clenbuterol, a selective beta(2)-adrenergic receptor agonist.
3 atment with 50 nM Compound 49b, a novel beta-adrenergic receptor agonist.
4 onist, or isoprenaline, a non-selective beta-adrenergic receptor agonist.
5 ation of UCP1 after stimulation with a beta3-adrenergic receptor agonist.
6 free [Ca2+] oscillations evoked by an alpha1 adrenergic receptor agonist.
7 nucleus when cells were treated with alpha1-adrenergic receptor agonist.
8 both amphetamine and guanfacine, an alpha2A adrenergic receptor agonist.
9 This is reversed by isoproterenol, a beta-adrenergic receptor agonist.
10 ase activity induced by UK14304, an alpha(2)-adrenergic receptor agonist.
11 nic fat cells that can be activated by beta3-adrenergic receptor agonists.
12 ed neonatal cardiac myocytes exposed to beta-adrenergic receptor agonists.
13 as acetylcholinesterase inhibitors and beta2 adrenergic receptor agonists.
14 preventing enhanced atrial responses to beta-adrenergic receptor agonists.
15 ance to therapeutic interventions with beta3-adrenergic receptor agonists.
16 sensitizes the channel to activation by beta-adrenergic receptor agonists.
17 ased sensitivity to the lipolytic effects of adrenergic receptor agonists.
18 threefold greater than that elicited by beta-adrenergic receptor agonists.
19 the anti-allodynic effect elicited by alpha2-adrenergic receptor agonists.
20 cardioprotective effects of an alpha-1A-AR (adrenergic receptor) agonist.
22 ells with phenylephrine, a specific alpha(1)-adrenergic receptor agonist, activated p70 S6 kinase but
23 tal secretion by secretin (through cAMP) and adrenergic receptor agonist activation (through Ca(2+)/P
24 myocardium to exogenous and endogenous beta-adrenergic receptor agonists after burn injury may be at
25 nsulin receptor substrate-1, as the alpha(1)-adrenergic receptor agonist also inhibited the platelet-
26 s study tests whether clonidine, an alpha(2)-adrenergic receptor agonist, alters excitatory glutamate
27 teristics in response to treatment with beta-adrenergic receptor agonists and activators of adenylate
28 l currently available therapies such as beta-adrenergic receptor agonists and antagonists, phosphodie
31 ume less oxygen after treatment with a beta3-adrenergic-receptor agonist and that they are sensitive
32 easured in response to isoproterenol, a beta-adrenergic receptor agonist, and carbachol, a cholinergi
34 chanism of Rett syndrome and introduce beta2-adrenergic receptor agonists as potential therapeutic ag
38 AR) in wound scarring, the ability of beta 2 adrenergic receptor agonist (beta2ARag) to alter HDF dif
39 ides were synthesized and evaluated as beta3-adrenergic receptor agonists (beta3-AR) for the treatmen
40 xpression and expansion can be rescued by B2 adrenergic receptor agonists but not sensory nerve agoni
41 otected myocytes from death induced by beta1-adrenergic receptor agonists by preventing cytosolic and
42 evealed that formoterol, a long-acting beta2 adrenergic receptor agonist, caused significant improvem
43 rality were treated with the selective beta3 adrenergic receptor agonist CL 316, 243 and underwent me
45 and given intraperitoneally either the beta3-adrenergic receptor agonist CL-316,243, 1 mg/kg (n = 8),
46 o cold temperatures or treated with the beta-adrenergic receptor agonist CL316,243 and that its expre
49 lementation of a high fat diet with a beta 3-adrenergic receptor agonist (CL316,243) prevented obesit
50 we report a role of Tregs in enhancing beta3-adrenergic receptor agonist CL316243 (CL)-stimulated the
53 Here, we show that treatment with the beta2-adrenergic receptor agonist clenbuterol increases surviv
55 dministration of the centrally acting alpha2-adrenergic receptor agonist, clonidine), and hypoxia and
56 eptor antagonist, prazosin, and the alpha(2)-adrenergic receptor agonist, clonidine, reduced the numb
57 her transdermal administration of the alpha2 adrenergic-receptor agonist, clonidine, can be used as a
58 line condition and an infusion of a alpha(2)-adrenergic receptor agonist, dexmedetomidine (10 min loa
60 induced by growth promoters, such as alpha1-adrenergic receptor agonists (e.g. phenylephrine (PE)).
61 ial agonists (eg, buprenorphine), and alpha2-adrenergic receptor agonists (eg, clonidine and lofexidi
63 activation in MDCK-D1 cells triggered by the adrenergic receptor agonist epinephrine and its mechanis
66 the dlPFC via pharmacological (the alpha(2A) adrenergic receptor agonist, guanfacine) or repetitive t
68 of this study was to determine whether alpha-adrenergic receptor agonists have a role in alveolar flu
69 ating airway obstructive diseases, and beta2 adrenergic receptor agonists have been the most commonly
70 hma exacerbation is the short-acting beta(2)-adrenergic receptor agonist; however, there is variation
71 t in the pancreas and blocked by an alpha(2)-adrenergic receptor agonist, implicating functional invo
72 an inhibit the Cl- current activated by beta-adrenergic receptor agonists in guinea-pig ventricular m
73 ced responsiveness to alpha(1)- and alpha(2)-adrenergic receptor agonists in skeletal muscle vasculat
76 with phenylephrine (PE), a specific alpha(1) adrenergic receptor agonist, increased protein synthesis
77 her insulin or phenylephrine (PE), an alpha1-adrenergic receptor agonist, induced Ser-9 phosphorylati
78 ice cold intolerant and insensitive to beta3 adrenergic receptor agonist-induced increase in whole-bo
79 Rho and inhibited the characteristic alpha1-adrenergic receptor agonist-induced myofibrillar organiz
83 d electrophysiological responses to the beta-adrenergic receptor agonist isoprenaline (Iso) in CA1 py
84 owing intra-LS injections of either the beta-adrenergic receptor agonist isoproterenol (10 mug or 30
88 reperfused with the addition of the beta(2)-adrenergic receptor agonist isoproterenol (iso), and rol
89 es, we show that norepinephrine and the beta-adrenergic receptor agonist isoproterenol also inhibited
90 were conducted using forskolin and the beta-adrenergic receptor agonist isoproterenol as agonists.
91 ministration of either the nonselective beta-adrenergic receptor agonist isoproterenol or the beta3-a
92 Both angiotensin II (Ang II) and the beta-adrenergic receptor agonist isoproterenol selectively in
93 ATP and UTP were not additive with the beta-adrenergic receptor agonist isoproterenol, but were syne
94 either alone or in the presence of the beta-adrenergic receptor agonist isoproterenol, failed to ind
95 ng periodic pacing in the presence of a beta-adrenergic receptor agonist isoproterenol, was significa
96 27 complex in response to the selective beta adrenergic receptor agonist isoproterenol, was subsequen
97 d enhanced inotropic sensitivity to the beta-adrenergic receptor agonist isoproterenol, with impairme
101 se-response curve of the effect of the beta2-adrenergic-receptor agonist isoproterenol was constructe
103 re incubated with forskolin or with the beta-adrenergic receptor agonist, isoproterenol, to stimulate
105 wing administration of isoproterenol, a beta-adrenergic receptor agonist known to induce cardiac inju
106 P) with a regularly used long-acting beta(2)-adrenergic receptor agonist (LABA) is well documented.
107 or in combination with a long-acting beta2 -adrenergic receptor agonist (LABA) on GCM in the bronchi
110 ytic effects we observed suggest that alpha2 adrenergic-receptor agonists may offer a pharmacologic m
112 sistent with this idea, the selective alpha1-adrenergic receptor agonist methoxamine was still able t
114 rbol 12-myristate 13-acetate or the alpha(1)-adrenergic receptor agonist norepinephrine via a mechani
116 vity by forskolin, cAMP analogs, or the beta-adrenergic receptor agonists norepinephrine and isoprote
118 o information exists regarding the effect of adrenergic receptor agonists on ductal secretion in a mo
119 pact of a dexmedetomidine infusion (alpha(2)-adrenergic receptor agonist) on muscle sympathetic postg
120 he effect of salmeterol, a long-acting beta2-adrenergic receptor agonist, on ovalbumin-induced plasma
121 e induction of these responses by the alpha1-adrenergic receptor agonist phenylephrine, whereas its i
122 luated the effects of the alpha-1 and beta-1 adrenergic receptor agonists (phenylephrine and dobutami
123 ly) or saline, the response to the a) alpha1-adrenergic receptor agonist, phenylephrine; b) endotheli
125 ent stimulation of beating rate by the beta2 adrenergic receptor agonist procaterol was significantly
126 f the two genotypes with a selective beta(3)-adrenergic receptor agonist produced similar increases i
127 me indicates that chronic exposure to alpha2-adrenergic receptor agonists produces strong dependence.
128 se receptors with BRL37344, a specific beta3-adrenergic receptor agonist, promoted migration that was
129 ments revealed that treatment with a beta(3)-adrenergic receptor agonist resulted in ligand-induced c
132 short-acting and long-acting inhaled beta(2)-adrenergic receptor agonists (SABA and LABA, respectivel
136 c TGF-beta type II receptor restored beta(2)-adrenergic receptor agonist-stimulated alveolar epitheli
138 iator of acute lung injury, inhibits beta(2)-adrenergic receptor agonist-stimulated vectorial fluid a
139 iration followed by instillation of an alpha-adrenergic receptor agonist such as phenylephrine, proce
141 uced in cultured myocardial cells by alpha1- adrenergic receptor agonists, such as phenylephrine (PE)
142 catecholamine agonists tested, only beta(1)-adrenergic receptor agonists supported encystation, wher
143 e after treatment with isoproterenol, a beta-adrenergic receptor agonist that causes turnover of palm
144 exmedetomidine (DEX; Precedex) is an alpha-2 adrenergic receptor agonist that produces anxiolysis and
145 ly controlled by corticosteroids and beta(2) adrenergic receptor agonists that target and relax airwa
148 es were treated with phenylephrine, an alpha-adrenergic receptor agonist, to drive HDACS out of the n
151 e and HPC through the infusion of the alpha2-adrenergic receptor agonist UK 14,304 impaired retrieval
152 (1.0 microm), and attenuated by the alpha(2)-adrenergic receptor agonist, UK 14,304 (1.0 microm), whi
153 ifically stimulated by the selective alpha2A-adrenergic receptor agonist UK14304 and by lysophosphati
154 turbed by intravenous injection of an alpha1-adrenergic receptor agonist, unilateral pressure changes
155 turbed by intravenous injection of an alpha1-adrenergic receptor agonist, unilateral pressure changes
157 pithelial bilayer, when stimulated with beta adrenergic receptor agonists, vasointestinal peptide, or
160 d some cells with Compound 49b, a novel beta-adrenergic receptor agonist we have reported previously
161 e development of orally bioavailable beta(3) adrenergic receptor agonists, we have identified a serie
162 of isoproterenol (a peripherally-acting beta-adrenergic receptor agonist) were administered in a doub
163 Significance statement: Clonidine, an alpha2-adrenergic receptor agonist, which decreases the level o
164 ere treated with CL-316243, a specific beta3-adrenergic receptor agonist, which sensitizes insulin ac
165 hat orally administered DL-isoproterenol, an adrenergic receptor agonist whose skeleton includes 1,2-
166 in Ts65Dn mice, formoterol or similar beta2 adrenergic receptor agonists with ability to cross the b
167 ndependent agonist) and terbutaline (beta(2)-adrenergic receptor agonist) with and without concurrent
168 hase of LTP by pairing isoproterenol, a beta-adrenergic receptor agonist, with a weak train, subthres
169 the effects of increasing doses of the beta2-adrenergic receptor agonist zinterol on Ca2+ transient a